This week we take a look at where orphan drugs might be in five years, pharma marketing to global markets, medication consumption patterns, how pharma can work with global online doctor networks, and the rise of e-prescribing:
– Orphan drugs – pharmaceutical treatments for rare diseases or disorders – have proven themselves as viable moneymakers, and the industry has taken note. FiercePharma’s Top 20 Orphan Drugs By 2018 covers results from EvaluatePharma’s 2013 Orphan Drug Report which reveals that orphan drugs are now showing a greater return on investment than products aimed at larger patient pools
– When it comes to getting your brand into the hands of consumers in different cultures the process can be vary widely from country to country. Who Buys Healthcare in Global Markets? from Paragraphs outlines that whom you market drugs, devices, and medical services in the U.S. are very different from those you’ll encounter in global markets and includes a free copy of their ‘Meeting 21st Century Challenges to Global Healthcare Brands’ briefing
– PSFK’s How Are People Taking Medication Today? includes an infographic from Mango Health created from collected data on how their community used their app by capturing the patterns in medication and nutritional supplement consumption, along with a video featuring Jason Oberfest, Founder of Mango Health, on the topic of Using Mobile To Inspire Healthier Lives
– What insights can independent online professional networks, which are used by more than three million doctors worldwide, provide on the way in which doctors prefer to engage with pharma? PMLiVE helps answer that, offering How To Work With Global Online Doctor Networks, a supplement sponsored by Networks in Health and their partners who share their expertise on a variety of digital engagement topics and provide insights into levels of digital activity
– The number of physicians doing e-prescribing jumped by 25% to 489,000 in 2012 compared to the previous year. 3 Things to Think About as e-Prescribing Becomes More Common from MedCity News highlights data from Alliance Life Sciences and Surescripts showing that the practice is reaching mainstream proportions
That wraps this week’s review of news from and for the pharma insight community. I’ll leave you with an invitation to learn more about the benefits of real time data and offer you a personal demo of InCrowd’s on-demand platform providing you direct and immediate access to Crowds of screened and targeted healthcare professionals.
If you have tips, suggestions or resources you’d like to share leave us a note below and please feel free to suggest topics that you’d like to see covered in future posts.
